Physician profile
Michael E Fath
NPI 1487631214
$1,656.08
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $120 · 2021: $761 · 2022: $124 · 2023: $37.22 · 2024: $58.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $95.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $95.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $440.43 | 2019-2021 | |
| Amgen INC. | $411.64 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $208.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $123.64 | 2021-2022 | |
| Abbvie INC. | $115.91 | 2021-2024 | |
| Pfizer INC. | $111.02 | 2019-2020 | |
| Glaxosmithkline, LLC. | $82.87 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.92 | 2021 | |
| Merck Sharp & Dohme LLC | $32.14 | 2021-2022 | |
| Amarin Pharma, INC. | $26.74 | 2019-2021 | |
| Novo Nordisk INC | $26.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.50 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.